COMPASS Pathways (CMPS) Q1 2026 earnings summary

Executive summary

• Delivered positive, highly statistically significant data from both pivotal Phase III studies for COMP360 in treatment-resistant depression (TRD), demonstrating rapid and durable efficacy not seen with current approved drugs in over 1,000 participants.

• FDA granted rolling NDA submission and review for COMP360 in TRD, with a Commissioner's National Priority Voucher (CNPV) awarded to potentially accelerate FDA review to 1–2 months.

• Final NDA submission is on track for Q4 2026, with launch readiness and commercial infrastructure expected by year-end.

• Advanced COMP360 development for PTSD, with late-stage trial design finalized, IND accepted by FDA, and leveraging VA collaborations.

• Strong commercial preparations include strategic collaborations, reimbursement infrastructure, and a rapidly expanding commercial team.

Financial highlights

• Net income for Q1 2026 was $91.2 million, compared to a net loss of $17.9 million in Q1 2025, primarily due to a $130.9 million non-cash gain on warrant fair value adjustment.

• Operating expenses decreased to $42.9 million from $49.6 million year-over-year, driven by lower R&D and G&A costs.

• Cash and cash equivalents totaled $466.0 million as of March 31, 2026, up from $149.6 million at year-end 2025.

• Debt increased to $50.5 million from $31.6 million over the same period.

• Accumulated deficit stood at $731.4 million.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures into 2028, excluding potential proceeds from outstanding PIPE warrants.

• 26-week data from COMP006 Part B expected in early Q3 2026, with launch readiness for COMP360 by year-end pending final data and regulatory review.

• Accelerated engagement with the DEA and state authorities to ensure timely rescheduling post-approval, with nearly 90% of the U.S. population in states prepared to reschedule within 30 days.

• Ongoing payer and formulary discussions to ensure broad and equitable access and reimbursement.

• Anticipates continued operating losses as R&D and commercialization activities increase, especially for COMP360 in TRD and PTSD.